In the News

A new discovery made by Memorial Sloan Kettering researchers and published in the journal <i>Nature Genetics</i>, identifies a mechanism for the triggering of solid tumors — including most types of cancers that affect children and young adults. For more information or to arrange interviews, e-mail Rebecca Williams at [email protected].

Taking a cue from smartphone technology, scientists are using face-recognition algorithms to improve RNA interference.

MSK researchers are learning how cells are able to recognize and correct errors that occur during cell division.

A freely accessible software program provides researchers with an easy way to optimize a popular genome-editing tool.

Learn how MSK specialists treat head and neck cancers using the most innovative approaches.

A retrospective study from MSK has found that colorectal cancer patients with liver metastases live an average of two years longer when they receive an additional treatment called hepatic arterial infusion (HAI).

MSK surgeon James Eastham explains the pros and cons of PSA testing and weighs in on a new US Preventive Services Task Force guideline.

Why do some patients respond to immunotherapy while others do not? Blood may hold the answer.

Researchers from Memorial Sloan Kettering Cancer Center (MSK) and their colleagues at the University of Pennsylvania (UPenn), in collaboration with the Parker Institute for Cancer Immunotherapy (PICI), studied changes in the blood of patients with stage IV melanoma who were all treated with the PD-1 drug pembrolizumab. Researchers looked at circulating immune cells called T cells that showed signs of being “reinvigorated” by the PD-1 therapy. For more information or to arrange interviews please e-mail Rebecca Williams at [email protected].

Learn more about entrectinib, a targeted therapy being evaluated in patients with solid tumors.